Secretin

1. Overview

Secretin is a 27-amino acid linear peptide hormone produced by enteroendocrine S cells of the duodenal and proximal jejunal mucosa. It holds a singular place in the history of endocrinology as the first hormone ever identified: in 1902, William Bayliss and Ernest Starling demonstrated that an acid extract of denervated jejunal mucosa, when injected intravenously, stimulated pancreatic secretion entirely independent of nervous control — an experiment that established the concept of chemical messengers carried by the blood and ultimately gave rise to the term "hormone" (from the Greek hormon, "to set in motion") [1][11].

The mature human secretin sequence is His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2, with a molecular weight of 3055.5 Da and a C-terminal amidation essential for biological activity [2][3]. The peptide is encoded by the SCT gene located on chromosome 11p15.5, which contains 4 exons and produces a 120-amino acid preprosecretin precursor that is cleaved to yield the mature 27-residue peptide [21]. Secretin belongs to the secretin/glucagon/VIP superfamily of peptide hormones; it shares 14 of 27 amino acid positions with glucagon, 10 with gastric inhibitory peptide (GIP), and 7 with vasoactive intestinal peptide (VIP) [3].

Secretin is released into the circulation when the luminal pH of the duodenum falls below approximately 4.5, triggered by the arrival of acidic gastric chyme through the pylorus. Its primary physiological actions are stimulation of bicarbonate-rich fluid secretion from pancreatic duct cells and enhancement of hepatic bile flow from cholangiocytes, both serving to neutralize duodenal acid and create the alkaline environment (pH 6–8) required for optimal digestive enzyme activity and fat digestion [3][4].

Clinically, secretin is FDA-approved as a diagnostic agent. Synthetic human secretin (ChiRhoStim) is used for pancreatic function testing, diagnosis of gastrinoma (Zollinger-Ellison syndrome) via the secretin stimulation test, identification of the ampulla of Vater during endoscopy, and secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) [12][13].

Molecular Weight

3055.5 Da

Sequence

27 amino acids (C-terminal amidated)

Half-life

~2.5–5 minutes (plasma)

Receptor

Secretin receptor (SCTR), class B GPCR, Gs-coupled

Routes

Intravenous (diagnostic use)

FDA Status

Approved diagnostic (ChiRhoStim, synthetic human secretin)

Source Cells

S cells of the duodenal and jejunal mucosa

2. Mechanism of Action

2.1 The Secretin Receptor (SCTR)

Secretin exerts its biological effects through the secretin receptor (SCTR), a class B (secretin family) G protein-coupled receptor (GPCR) expressed on the basolateral membrane of pancreatic duct epithelial cells, cholangiocytes, gastric parietal and chief cells, Brunner gland epithelium, renal tubular cells, and multiple neuronal populations [3][10][20]. The SCTR is a prototypical member of the class B GPCR family, which also includes receptors for glucagon, GLP-1, VIP, PACAP, and calcitonin. Structurally, it features a large extracellular N-terminal domain that forms the primary ligand-binding site and a seven-transmembrane helical domain that mediates G protein coupling [10].

2.2 Signal Transduction

Upon secretin binding, the SCTR couples primarily to Gs-alpha, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP) concentrations [3][20]. The cAMP/protein kinase A (PKA) pathway is the central signaling cascade through which secretin drives its major physiological effects:

1. cAMP generation — Secretin binding activates adenylyl cyclase, converting ATP to cAMP, which serves as the principal second messenger.
2. PKA activation — Elevated cAMP activates protein kinase A, which phosphorylates downstream targets including the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel.
3. CFTR-mediated anion transport — Phosphorylated CFTR opens in the apical membrane, allowing Cl- efflux. The resulting chloride gradient drives the Cl-/HCO3- anion exchanger (AE2), producing net bicarbonate secretion into the ductal lumen.
4. Aquaporin-mediated water transport — Osmotic gradients created by bicarbonate and chloride secretion drive water movement into the lumen via aquaporins, producing the characteristic high-volume, bicarbonate-rich pancreatic juice.

In addition to Gs/cAMP signaling, SCTR can also engage Gq-mediated phospholipase C (PLC) activation, increasing intracellular calcium and activating protein kinase C (PKC) in certain cell types, though this pathway is secondary to the dominant cAMP cascade [20].

2.3 Pancreatic Bicarbonate Secretion

Secretin is the principal hormonal stimulus for pancreatic ductal (as opposed to acinar) secretion [3][4]. While cholecystokinin (CCK) primarily drives acinar cell enzyme secretion, secretin stimulates duct cells to produce a large volume of alkaline fluid containing bicarbonate concentrations as high as 120–140 mEq/L. This bicarbonate-rich secretion neutralizes gastric acid entering the duodenum, raising luminal pH from approximately 2 to 6–8 and thereby creating optimal conditions for the activity of pancreatic lipase, trypsin, and other digestive enzymes [4][22].

The coupling of secretin to CFTR-mediated bicarbonate transport has direct clinical significance: in cystic fibrosis, loss-of-function mutations in the CFTR gene impair secretin-stimulated ductal secretion, contributing to inspissated secretions, ductal obstruction, and progressive pancreatic destruction [3].

2.4 Hepatic Bile Flow

Secretin stimulates choleresis (bile flow) by acting on cholangiocytes — the epithelial cells lining intrahepatic and extrahepatic bile ducts [16]. The mechanism parallels that in pancreatic ducts: secretin binds SCTR on the basolateral membrane of large cholangiocytes, activating the cAMP/PKA pathway, which phosphorylates apical CFTR, promotes Cl- efflux, and drives AE2-mediated HCO3- secretion into the bile ductular lumen [16]. Additionally, secretin induces exocytosis of intracellular vesicles containing aquaporins and transporters to the apical membrane, increasing the fluid-secretory capacity of the biliary epithelium [16]. Vacuolar H+-ATPase on the apical membrane also participates by secreting H+ ions that contribute to the overall bicarbonate secretion process. This ductular bicarbonate secretion is termed "ductular bile" or "bile salt-independent bile flow" and constitutes approximately 30% of total bile volume.

2.5 Additional Physiological Effects

• Gastric acid inhibition — Secretin inhibits gastric acid secretion by parietal cells, providing a negative feedback loop: as acid entering the duodenum triggers secretin release, the secretin in turn suppresses further acid output [4].
• Gastrin modulation — In normal physiology, secretin inhibits gastrin release from G cells. Paradoxically, in gastrin-secreting tumors (gastrinomas), secretin causes a marked increase in gastrin release — the basis of the secretin stimulation test for Zollinger-Ellison syndrome [17].
• Sphincter of Oddi — Secretin transiently increases the tone of the sphincter of Oddi, which temporarily impedes outflow and promotes distension of the pancreatic duct — a property exploited in secretin-enhanced MRCP imaging [14][23].
• Pepsin secretion — Secretin stimulates pepsinogen release from gastric chief cells.

3. Researched Applications

Pancreatic Exocrine Function Testing (Strong Evidence — FDA Approved)

The secretin-stimulated pancreatic function test is the gold-standard direct method for assessing pancreatic exocrine reserve [4][12][22]. In the endoscopic pancreatic function test (ePFT), synthetic human secretin (0.2 mcg/kg IV) is administered and duodenal fluid is aspirated at timed intervals over 60 minutes. Bicarbonate concentration in the aspirated fluid is measured as a marker of ductal cell function, with a peak bicarbonate concentration <80 mEq/L considered indicative of chronic pancreatitis. This test can detect early-stage chronic pancreatitis before morphological changes become apparent on imaging, making it valuable for patients with unexplained abdominal pain or steatorrhea with normal cross-sectional imaging [4][22].

Gastrinoma Diagnosis — Secretin Stimulation Test (Strong Evidence — FDA Approved)

The secretin stimulation test is used to diagnose gastrinoma (Zollinger-Ellison syndrome) in patients with intermediate fasting serum gastrin levels (150–1000 pg/mL) and acid hypersecretion [17]. Secretin (2 CU/kg or 0.4 mcg/kg) is administered as a rapid IV bolus over 1 minute, and serum gastrin is measured at baseline and at 2, 5, 10, 15, 20, and 30 minutes post-injection. In normal subjects and patients with other causes of hypergastrinemia, secretin either has no effect or slightly decreases gastrin levels. In patients with gastrinoma, secretin causes a paradoxical and marked increase in gastrin: an incremental rise of >120 pg/mL (some centers use >200 pg/mL) from baseline is considered a positive test with reported sensitivity of approximately 85–90% and high specificity for gastrinoma [17]. The test is particularly useful in MEN1 patients with borderline gastrin elevations, enabling early detection of gastrinomas before they become clinically overt.

Proton pump inhibitors must be discontinued at least 1–2 weeks before testing (preferably 2 weeks), and H2 receptor antagonists stopped at least 48–72 hours prior, as these medications can cause false-positive results by elevating baseline gastrin levels [17].

Secretin-Enhanced MRCP (Strong Evidence — FDA Approved)

Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) exploits secretin's stimulation of pancreatic fluid output and transient increase in sphincter of Oddi tone to improve visualization of the pancreatic ductal system [14][23]. After IV secretin administration (0.2 mcg/kg), the resulting fluid distension of the pancreatic duct and side branches enhances their depiction on heavily T2-weighted MR sequences. Clinical applications include evaluation of pancreatic divisum, sphincter of Oddi dysfunction, early chronic pancreatitis, intraductal papillary mucinous neoplasm (IPMN) communication with the main duct, post-surgical anatomy, and assessment of exocrine pancreatic reserve by measuring duodenal filling [14][23].

Identification of Ampulla of Vater (Approved Use)

During endoscopic retrograde cholangiopancreatography (ERCP) or other endoscopic procedures, secretin administration causes visible flow of pancreatic juice from the major papilla, aiding in identification of the ampulla of Vater and accessory papilla [13].

Autism Spectrum Disorder (Disproven — No Benefit)

In 1998, Horvath et al. published a case series of three children with autism who appeared to show improved social and language skills following secretin infusion during a GI diagnostic procedure [6]. This uncontrolled observation received extensive media coverage, leading to widespread off-label use of secretin for autism despite the absence of rigorous evidence.

The first rigorous refutation came from Sandler et al. (1999), who conducted a double-blind, placebo-controlled trial in 60 children ages 3–14 with autism or pervasive developmental disorder. The study found no significant improvement on any behavioral, language, or developmental outcome measure with secretin compared to saline placebo [7].

Subsequent controlled investigations confirmed these negative results. A 2005 review by Esch et al. examined 15 double-blind randomized controlled trials and concluded that secretin was ineffective for pervasive developmental disabilities [9]. A 2011 systematic review by Krishnaswami et al., analyzing 7 high-quality RCTs, found no evidence of effectiveness for any ASD symptom domain including language, communication, symptom severity, or social skills [8]. The secretin–autism episode is now widely cited in the medical literature as a cautionary example of how anecdotal reports, media amplification, and desperate demand can drive premature adoption of unproven treatments [8][9].

Gut-Brain Axis and Central Effects (Emerging Research)

Secretin and its receptor are expressed in multiple brain regions including the hypothalamus (paraventricular nucleus, supraoptic nucleus, arcuate nucleus), nucleus tractus solitarius, cerebellum, hippocampus, central amygdala, and cerebral cortex [5][18]. Central secretin modulates dopamine turnover, prolactin secretion, cAMP signaling, and vasopressin release. Animal studies have demonstrated that secretin influences food and water intake, social interaction, spatial learning, motor coordination, and motor learning through these central pathways [18][19]. The secretin-mediated gut-brain axis, including a recently described secretin–brown adipose tissue–brain circuit for satiety signaling, represents an active frontier of research [19].

4. Clinical Evidence Summary

5. Dosing in Research

The FDA-approved synthetic human secretin product (ChiRhoStim) is administered intravenously in clinical diagnostic settings [13]. Dosing varies by indication:

Pancreatic function testing: A dose of 0.2 mcg/kg is administered as an IV bolus. Duodenal fluid is collected via endoscopic aspiration at 15-minute intervals for 60 minutes. Peak bicarbonate concentration is measured as the primary endpoint [12][22].

Secretin stimulation test for gastrinoma: A dose of 0.4 mcg/kg (or 2 CU/kg) is given as a rapid IV bolus over approximately 1 minute. Blood samples for serum gastrin measurement are drawn at baseline (two samples 5 minutes apart) and at 2, 5, 10, 15, 20, and 30 minutes post-injection [17]. No fasting-state test dose is required with the synthetic human product; however, a 0.1 mL test dose was historically recommended with porcine-derived secretin to screen for allergic reactions [12].

Secretin-enhanced MRCP: A dose of 0.2 mcg/kg is given as a slow IV bolus. Dynamic MRCP sequences are acquired over 10–15 minutes to capture progressive duct filling and duodenal fluid accumulation [14][23].

After intravenous bolus administration of 0.4 mcg/kg, plasma secretin concentrations decline rapidly, returning to baseline within 60–90 minutes in most subjects. The plasma half-life of exogenous secretin is approximately 2.5–5 minutes [3][12].

6. Safety and Side Effects

The safety profile of secretin has been characterized across clinical trials involving over 980 patients receiving the synthetic human product (SecreFlo/ChiRhoStim) [12][13].

Common adverse reactions. The most frequently reported side effect is transient flushing of the face, neck, and chest, occurring immediately after injection. This is generally mild, self-limiting, and requires no intervention.

Uncommon adverse reactions. Less common side effects include nausea, vomiting, abdominal discomfort, diarrhea, transient mild hypotension, and brief episodes of tachycardia. In the SecreFlo clinical program of over 981 patients and 24 healthy volunteers, adverse events were occasional and mild [12].

Allergic reactions. Although allergic reactions were a concern with porcine-derived secretin products, no allergic reactions were observed after test dose or full dose of the synthetic human secretin product (SecreFlo) in clinical trials [12]. Nevertheless, the prescribing information recommends having resuscitation equipment available. Porcine secretin (no longer widely available) carried a higher risk of anaphylactoid reactions due to potential immunogenicity of the non-human peptide.

Drug interactions. Anticholinergic agents may blunt the pancreatic response to secretin, potentially causing false-negative results on pancreatic function testing. Conversely, proton pump inhibitors and H2 receptor antagonists can elevate baseline gastrin levels, potentially causing false-positive results on the secretin stimulation test for gastrinoma. PPIs should be stopped at least 1–2 weeks (ideally 2 weeks) and H2 blockers at least 48–72 hours before secretin-based diagnostic testing [13][17].

Contraindications. Secretin is contraindicated in patients with known hypersensitivity to secretin or any formulation component. Caution is advised in patients with a history of vagotomy, inflammatory bowel disease, or pancreatic or biliary duct obstruction (where stimulation of secretion against a fixed obstruction could theoretically elevate ductal pressures) [13].

Pregnancy and lactation. Secretin is classified as pregnancy category C; it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Excretion in human breast milk is unknown.

7. Comparison with CCK

Secretin and cholecystokinin (CCK) are the two principal hormonal regulators of exocrine pancreatic secretion, but they target different cell populations and produce distinct secretory profiles [22]:

| Feature | Secretin | CCK | |---|---|---| | Primary target cells | Pancreatic duct cells, cholangiocytes | Pancreatic acinar cells, gallbladder | | Primary secretory product | HCO3--rich, high-volume fluid | Enzyme-rich (lipase, trypsinogen, amylase) | | Release stimulus | Duodenal acid (pH <4.5) | Fatty acids, amino acids in duodenal lumen | | Receptor type | SCTR (class B GPCR, Gs-coupled) | CCK-A/CCK-1 (class A GPCR, Gq-coupled) | | Second messenger | cAMP/PKA | IP3/Ca2+/PKC | | Interaction | Potentiates CCK-stimulated enzyme secretion | Potentiates secretin-stimulated fluid secretion |

Secretin and CCK exhibit strong potentiation: submaximal doses of both hormones together produce pancreatic output greater than the sum of either alone. The combined secretin-CCK test was historically used for comprehensive assessment of both ductal and acinar function, though secretin alone is now more commonly employed for standardized pancreatic function testing [22].

8. Historical Significance

The discovery of secretin by Bayliss and Starling in January 1902 at University College London represents one of the most important experiments in the history of physiology [1][11]. Prior to this discovery, it was universally assumed that all coordination of organ function was mediated by the nervous system, following the prevailing Pavlovian model of reflex control. Bayliss and Starling's critical experiment involved denervating a loop of jejunum in an anesthetized dog, then introducing hydrochloric acid into the denervated loop. Despite the absence of any nerve connections, the pancreas responded with copious secretion. They then prepared an acid extract of the jejunal mucosa, injected it intravenously, and observed the same pancreatic response — proving that a chemical substance ("secretin") released from the intestinal lining traveled through the blood to the pancreas [1].

Starling subsequently coined the term "hormone" in his 1905 Croonian Lectures to describe this class of chemical messengers. The secretin discovery thus inaugurated the entire field of endocrinology and established the paradigm that organs communicate not only through nerves but through bloodborne chemical signals [11].

The complete amino acid sequence of porcine secretin was determined by Mutt and Jorpes in 1966–1968 [2], and the human secretin sequence (identical to the porcine sequence) was subsequently confirmed.

9. Regulatory Status

United States (FDA). Porcine secretin (SecreFlo) was the first FDA-approved secretin product. Synthetic human secretin (ChiRhoStim, manufactured by ChiRhoClin, Inc.) received FDA approval in 2004 for stimulation of pancreatic secretions for diagnostic testing, diagnosis of gastrinoma, and facilitation of identification of the ampulla of Vater during endoscopy [13]. SecreFlo (porcine-derived) is no longer commercially available; ChiRhoStim is the only currently marketed secretin product in the United States.

Autism indication. Secretin has never received FDA approval for the treatment of autism spectrum disorder. Following the negative results of multiple controlled trials, the FDA issued public advisories cautioning against off-label use of secretin for autism [8][9].

10. Related Peptides

See also: Vasoactive Intestinal Peptide (VIP), Glucagon

11. References

1. [1] Bayliss WM, Starling EH. (1902). The mechanism of pancreatic secretion. J Physiol. DOI PubMed
2. [2] Mutt V, Jorpes JE. (1968). Structure of porcine secretin. The amino acid sequence. Eur J Biochem. DOI PubMed
3. [3] Afroze S, Meng F, Jensen K, et al. (2013). The physiological roles of secretin and its receptor. Ann Transl Med. DOI PubMed
4. [4] Chey WY, Chang TM. (2003). Secretin, 100 years later. J Gastroenterol. DOI PubMed
5. [5] Chu JY, Chung SC, Lam AK, et al. (2002). Secretin as a neuropeptide. Mol Neurobiol. DOI PubMed
6. [6] Horvath K, Stefanatos G, Sokolski KN, et al. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. PubMed
7. [7] Sandler AD, Sutton KA, DeWeese J, et al. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. DOI PubMed
8. [8] Krishnaswami S, McPheeters ML, Veenstra-VanderWeele J. (2011). A systematic review of secretin for children with autism spectrum disorders. Pediatrics. DOI PubMed
9. [9] Esch RV, Levy MJ, et al. (2005). Secretin is an ineffective treatment for pervasive developmental disabilities — a review of 15 double-blind randomized controlled trials. Res Dev Disabil. DOI PubMed
10. [10] Dong M, Lam PC, Pinon DI, et al. (2012). Ligand binding and activation of the secretin receptor. Br J Pharmacol. DOI PubMed
11. [11] Hunsballe JM. (2001). Secretin, its discovery, and the introduction of the hormone concept. Scand J Clin Lab Invest Suppl. DOI PubMed
12. [12] FDA. (2002). Drug Approval Package — SecreFlo (Secretin) NDA. FDA Access Data. PubMed
13. [13] FDA. (2004). Drug Approval Package — Human Secretin Injection (ChiRhoStim) NDA. FDA Access Data. PubMed
14. [14] Manfredi R, Defined M, Brizi MG, et al. (2013). Secretin-enhanced MR cholangiopancreatography — spectrum of findings. RadioGraphics. DOI PubMed
15. [15] Mariani A, Curioni S, Zanello A, et al. (2003). Secretin MRCP and endoscopic pancreatic manometry in the evaluation of sphincter of Oddi function. Gastrointest Endosc. DOI PubMed
16. [16] Chung SA, Rotondo A, Bhardwaj R, et al. (1992). Secretin stimulates bile ductular secretory activity through the cAMP system. Am J Physiol. DOI PubMed
17. [17] Pisegna JR, Ohning GV, Gao Y, et al. (2000). Secretin stimulation test for gastrinoma diagnosis. Gastroenterology. PubMed
18. [18] Ng SS, Yung WH, Chow BK. (2014). The central mechanisms of secretin in regulating multiple behaviors. Front Endocrinol. DOI PubMed
19. [19] Li Y, Schnabl K, Gabler SM, et al. (2023). Secretin modulates appetite via brown adipose tissue–brain axis. Eur J Nucl Med Mol Imaging. DOI PubMed
20. [20] Siu FK, Lam IP, Chu JY, Chow BK. (2006). Signaling mechanisms of secretin receptor. Regul Pept. DOI PubMed
21. [21] Whitcomb DC, Ertan A. (2000). Human secretin (SCT) — gene structure, chromosome location, and distribution of mRNA. Cytogenet Cell Genet. DOI PubMed
22. [22] DiMagno EP, Malagelada JR, Go VLW. (1974). A comparison between secretin alone and sequential secretin–CCK in assessment of pancreatic function. Gastroenterology. PubMed
23. [23] Graziani R, Frulloni L, Mantovani W, et al. (2016). Secretin-stimulated MR cholangiopancreatography — spectrum of findings in pancreatic diseases. Insights Imaging. DOI PubMed